Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

The Supernatant of Tonsil-Derived Mesenchymal Stem Cell Has Antiallergic Effects in Allergic Rhinitis Mouse Model

“…It is characterized by Th2 immune response with an increased influx of eosinophils [1]. To date, various treatment options have been introduced to treat AR patients, including medical treatment, surgery, and antigenspecific immunotherapy [2]. However, the recurrences of symptoms are common problems after drug withdrawal and surgery.…”

Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence

“…70 They will represent the change management strategy of ARIA, phase 4. 16 The 2017 MASK treatment study confirms MASK's usefulness in assessing behavior in patients with allergic rhinitis. A ranking of medications was possible and confirmed the MASK 2016 study.…”

“…14,15 Moreover, guidelines (in rhinitis but also in asthma) have led to a better understanding of the treatment of the disease and have had an important teaching role that has led to change management. 16 In addition, there is a need to support transformation of the health care system for integrated care with organizational health literacy. 16,17 During a recent meeting held in Paris (December 3, 2018) for chronic disease care, Mobile Airways Sentinel Network (MASK) 18 and Impact of Air Pollution on Asthma and Rhinitis (POLLAR; European Institute for Innovation and Technology-Health [EIT Health]), 19 in collaboration with professional and patient organizations in the field of allergy and airway diseases (Fig 1), recommended the evaluation of real-life care pathways (integrated care pathways [ICPs]) centered around the patient with rhinitis and asthma.…”

“…During the ICP meeting in Paris, next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for allergic rhinitis, 5,[20][21][22] RWE provided by randomized controlled trials, real-world data using mobile technology, 23,24 and chamber studies (Fig 2). 5,6,[16][17][18][19][20][25][26][27] These recommendations were used to refine the algorithm for allergic rhinitis treatment proposed by a consensus group. 5 The present report describes the process of next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA)-GRADE guidelines for the pharmacologic treatment of allergic rhinitis.…”

Keep the cat, change the care pathway: A transformational approach to managing Fel d 1, the major cat allergen

“…ICPs have been proposed with a focus on mHealth technologies that should enhance self‐management and adherence to guidelines and ICPs. An innovative patient‐centered approach for ICPs has been proposed by the ARIA expert group for rhinitis and asthma multi‐morbidity …”